semaglutide – Page 3

Semaglutide Shows Promise in Reducing Alcohol Consumption, Small Study Reveals

9 months ago talkbio0Tagged addiction, Alcohol Use Disorder, Craving for alcohol, Glucagon-Like Peptide 1, semaglutide, Wegovy, Weight Loss Medication

semaglutide, Ozempic, Wegovy, alcohol use disorder, GLP-1 drugs, alcohol cravings, weight loss medication, addiction treatment

FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease

9 months ago talkbio0Tagged Agonist, Approved, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes, GLP-1 receptor, Kidney Diseases, Ozempic, Risk, semaglutide, United States Food and Drug Administration

Ozempic, FDA Approval, Type 2 Diabetes, Chronic Kidney Disease (CKD), Kidney Disease Risks, Cardiovascular Disease Risks, Semaglutide, GLP-1 Receptor Agonist

Veru’s Enobosarm Reduces Lean Mass Loss in Patients Taking Wegovy for Weight Reduction

9 months ago talkbio0Tagged Agonist, enobosarm, GLP-1 receptor, Lean mass preservation, Obesity, sarcopenic, semaglutide, Wegovy, Weight Loss

Enobosarm, Wegovy (semaglutide), Lean mass preservation, Weight loss, Sarcopenic obesity, GLP-1 receptor agonist

Novo Nordisk’s Obesity Drug Breakthrough: 22% Weight Loss at Week 36 Boosts Stock by 11%

10 months ago talkbio0Tagged 22%, amycretin, Drug Industry, next-gen, Nordisk, Obesity, semaglutide, Stock Surge, Weight Loss

Novo Nordisk, Obesity drug, 22% weight loss, Stock surge, Next-gen obesity treatment, Amycretin, Semaglutide, Pharmaceutical industry

High-Dose Wegovy Demonstrates Enhanced Weight Loss in Phase III Trial

10 months ago talkbio0Tagged Nordisk, Novo Nordisk, Obesity, Phase 3 Clinical Trials, semaglutide, Step (specific stage), Up, Wegovy

Wegovy, semaglutide, obesity treatment, weight loss, Novo Nordisk, Phase III trial, STEP UP trial

Novo Nordisk’s High-Dose Wegovy Demonstrates Superior Weight Loss of 20.7% in Phase IIIb Trial

10 months ago talkbio0Tagged Nordisk, Obesity, semaglutide, Step (specific stage), Trial Phase 3B, Up, Wegovy

Novo Nordisk, Wegovy, semaglutide, obesity treatment, weight loss, Phase IIIb trial, STEP UP trial

CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial, Falling Short of 25% Target

11 months ago talkbio0Tagged cagrilintide, CagriSema, Nordisk, Obesity, Phase 3 REDEFINE 1 Trial, semaglutide, Weight Loss

CagriSema, Weight Loss, Phase 3 REDEFINE 1 Trial, Obesity Treatment, Novo Nordisk, Semaglutide, Cagrilintide

FDA Confirms Tirzepatide Availability, Compounders Express Concerns, While Semaglutide Shortage Persists

11 months ago talkbio0Tagged Availability of, Compounders, Dosage Forms, Drug Shortage, Glucagon-Like Peptide 1, semaglutide, United States Food and Drug Administration

FDA, tirzepatide, semaglutide, GLP-1 drug shortage, compounders, pharmaceutical availability

Novo Nordisk’s Vision for the Future of GLP-1 Therapies: Expanding Beyond Diabetes and Obesity

11 months ago talkbio0Tagged advancements, agonists, Chronic disease, Diabetes Mellitus, Non-Insulin-Dependent, Future, Glucagon-Like Peptide 1, Nordisk, Obesity, semaglutide

GLP-1 agonists, Novo Nordisk, Type 2 diabetes, Obesity, Future treatments, Chronic diseases, Semaglutide, Tirzepatide, Therapeutic advancements

EU Regulator to Investigate Potential Link Between Ozempic and Rare Eye Condition NAION

11 months ago talkbio0Tagged Agencies, Diabetes, European (ethnic group), Evaluation, NAION, Nordisk, Ozempic, semaglutide

Ozempic, NAION, European Medicines Agency, Novo Nordisk, semaglutide, eye disorder, diabetes drug, investigation